PortalPublikationenMedical androgen deprivation therapy and increased non-cance...

Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years

Standard

Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. / Abdollah, F; Sammon, J D; Reznor, G; Sood, A; Schmid, M; Klett, D E; Sun, M; Aizer, A A; Choueiri, T K; Hu, J C; Kim, S P; Kibel, A S; Nguyen, P L; Menon, M; Trinh, Q-D.

in: EJSO-EUR J SURG ONC, Jahrgang 41, Nr. 11, 11.2015, S. 1529-1539.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung

Harvard

Abdollah, F, Sammon, JD, Reznor, G, Sood, A, Schmid, M, Klett, DE, Sun, M, Aizer, AA, Choueiri, TK, Hu, JC, Kim, SP, Kibel, AS, Nguyen, PL, Menon, M & Trinh, Q-D 2015, 'Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years', EJSO-EUR J SURG ONC, Jg. 41, Nr. 11, S. 1529-1539. https://doi.org/10.1016/j.ejso.2015.06.011

APA

Abdollah, F., Sammon, J. D., Reznor, G., Sood, A., Schmid, M., Klett, D. E., Sun, M., Aizer, A. A., Choueiri, T. K., Hu, J. C., Kim, S. P., Kibel, A. S., Nguyen, P. L., Menon, M., & Trinh, Q-D. (2015). Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. EJSO-EUR J SURG ONC, 41(11), 1529-1539. https://doi.org/10.1016/j.ejso.2015.06.011

Vancouver

Abdollah F, Sammon JD, Reznor G, Sood A, Schmid M, Klett DE et al. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. EJSO-EUR J SURG ONC. 2015 Nov;41(11):1529-1539. https://doi.org/10.1016/j.ejso.2015.06.011

Bibtex

@article{7013bc7cd2b441c39718bfec3a8fdfd0,
title = "Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years",
abstract = "PURPOSE: To examine the potential relationship between androgen deprivation therapy and other-cause mortality (OCM) in patients with prostate cancer treated with medical primary-androgen deprivation therapy, prostatectomy, or radiation.METHODS: A total of 137,524 patients with non-metastatic PCa treated between 1995 and 2009 within the Surveillance Epidemiology and End Results Medicare-linked database were included. Cox-regression analysis tested the association of ADT with OCM. A 40-item comorbidity score was used for adjustment.RESULTS: Overall, 9.3% of patients harbored stage III-IV disease, and 57.7% of patients received ADT. The mean duration of ADT exposure was 22.9 months (median: 9.1; IQR: 2.8-31.5). Mean and median follow-up were 66.9, and 60.4 months, respectively. At 10 years, overall-OCM rate was 36.5%; it was 30.6% in patients treated without ADT vs. 40.1% in patients treated with ADT (p < 0.001). In multivariable-analysis, ADT was associated with an increased risk of OCM (Hazard-ratio [HR]: 1.11, 95% Confidence-interval [95% CI]: 1.08-1.13). Patients with no comorbidity (10-year OCM excess risk: 9%) were more subject to harm from ADT than patients with high comorbidity (10-year OCM excess risk: 4.7%).CONCLUSIONS: In patients with PCa, treatment with medical ADT may increase the risk of mortality due to causes other than PCa. Whether this is a simple association or a cause-effect relationship is unknown and warrants further study in prospective studies.",
author = "F Abdollah and Sammon, {J D} and G Reznor and A Sood and M Schmid and Klett, {D E} and M Sun and Aizer, {A A} and Choueiri, {T K} and Hu, {J C} and Kim, {S P} and Kibel, {A S} and Nguyen, {P L} and M Menon and Q-D Trinh",
note = "Copyright {\textcopyright} 2015 Elsevier Ltd. All rights reserved.",
year = "2015",
month = nov,
doi = "10.1016/j.ejso.2015.06.011",
language = "English",
volume = "41",
pages = "1529--1539",
journal = "EJSO-EUR J SURG ONC",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "11",

}

RIS

TY - JOUR

T1 - Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years

AU - Abdollah, F

AU - Sammon, J D

AU - Reznor, G

AU - Sood, A

AU - Schmid, M

AU - Klett, D E

AU - Sun, M

AU - Aizer, A A

AU - Choueiri, T K

AU - Hu, J C

AU - Kim, S P

AU - Kibel, A S

AU - Nguyen, P L

AU - Menon, M

AU - Trinh, Q-D

N1 - Copyright © 2015 Elsevier Ltd. All rights reserved.

PY - 2015/11

Y1 - 2015/11

N2 - PURPOSE: To examine the potential relationship between androgen deprivation therapy and other-cause mortality (OCM) in patients with prostate cancer treated with medical primary-androgen deprivation therapy, prostatectomy, or radiation.METHODS: A total of 137,524 patients with non-metastatic PCa treated between 1995 and 2009 within the Surveillance Epidemiology and End Results Medicare-linked database were included. Cox-regression analysis tested the association of ADT with OCM. A 40-item comorbidity score was used for adjustment.RESULTS: Overall, 9.3% of patients harbored stage III-IV disease, and 57.7% of patients received ADT. The mean duration of ADT exposure was 22.9 months (median: 9.1; IQR: 2.8-31.5). Mean and median follow-up were 66.9, and 60.4 months, respectively. At 10 years, overall-OCM rate was 36.5%; it was 30.6% in patients treated without ADT vs. 40.1% in patients treated with ADT (p < 0.001). In multivariable-analysis, ADT was associated with an increased risk of OCM (Hazard-ratio [HR]: 1.11, 95% Confidence-interval [95% CI]: 1.08-1.13). Patients with no comorbidity (10-year OCM excess risk: 9%) were more subject to harm from ADT than patients with high comorbidity (10-year OCM excess risk: 4.7%).CONCLUSIONS: In patients with PCa, treatment with medical ADT may increase the risk of mortality due to causes other than PCa. Whether this is a simple association or a cause-effect relationship is unknown and warrants further study in prospective studies.

AB - PURPOSE: To examine the potential relationship between androgen deprivation therapy and other-cause mortality (OCM) in patients with prostate cancer treated with medical primary-androgen deprivation therapy, prostatectomy, or radiation.METHODS: A total of 137,524 patients with non-metastatic PCa treated between 1995 and 2009 within the Surveillance Epidemiology and End Results Medicare-linked database were included. Cox-regression analysis tested the association of ADT with OCM. A 40-item comorbidity score was used for adjustment.RESULTS: Overall, 9.3% of patients harbored stage III-IV disease, and 57.7% of patients received ADT. The mean duration of ADT exposure was 22.9 months (median: 9.1; IQR: 2.8-31.5). Mean and median follow-up were 66.9, and 60.4 months, respectively. At 10 years, overall-OCM rate was 36.5%; it was 30.6% in patients treated without ADT vs. 40.1% in patients treated with ADT (p < 0.001). In multivariable-analysis, ADT was associated with an increased risk of OCM (Hazard-ratio [HR]: 1.11, 95% Confidence-interval [95% CI]: 1.08-1.13). Patients with no comorbidity (10-year OCM excess risk: 9%) were more subject to harm from ADT than patients with high comorbidity (10-year OCM excess risk: 4.7%).CONCLUSIONS: In patients with PCa, treatment with medical ADT may increase the risk of mortality due to causes other than PCa. Whether this is a simple association or a cause-effect relationship is unknown and warrants further study in prospective studies.

U2 - 10.1016/j.ejso.2015.06.011

DO - 10.1016/j.ejso.2015.06.011

M3 - SCORING: Journal article

C2 - 26210655

VL - 41

SP - 1529

EP - 1539

JO - EJSO-EUR J SURG ONC

JF - EJSO-EUR J SURG ONC

SN - 0748-7983

IS - 11

ER -